A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Beijing Konruns Pharmaceutical Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
Shanghai Chest Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Second Affiliated Hospital, School of Medicine, Zhejiang University
Jinling Hospital, China
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences